Autopsy report · NCT07192237
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Cause of deathOther
“PI requested”
Life of this trial
- Registered 7 months before it started.
- Suspended: paused, and may or may not restart.
- 40 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Phase 2 Study; Blinatumomab; Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab
- Participants
- 40 (planned, not actual)
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.